Eli Lilly and Company announced Tuesday it was investing more than $6 billion in a new manufacturing facility in Huntsville, Alabama.

The next-generation synthetic medicine active pharmaceutical ingredient facility will produce small molecule synthetic and peptide medicines. It is the third of four new U.S. sites Lilly plans to announce.

The site will be among those that will manufacture orforglipron, Lilly’s first oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of this year.

David A. Ricks, Lilly chair and CEO, said the facility would produce medications “for illnesses of all kinds.”

He specifically mentioned heart medications and medications for brain illnesses in addition to obesity medications.

L

See Full Page